Skip to content

GlobeStar Therapeutics Corp: financial reference

Explore GlobeStar Therapeutics Corp financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Filing record ends 2024-01-19

The latest filing in this captured record is a 10-K filed 2024-01-19. No later filing is in the SEC companyfacts record captured on 2026-09-21. GlobeStar Therapeutics Corp may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2022-09-309,915USD2024-01-19
Total liabilitiesAt date2023-09-301,433,861USD2024-01-19
Stockholders equityAt date2023-09-30-1,433,861USD2024-01-19
Cash and cash equivalentsAt date2022-09-306,365USD2024-01-19
Net income or loss2022-10-012023-09-30-1,949,249USD2024-01-19
Operating cash flow2022-10-012023-09-30-205,760USD2024-01-19
Capital expenditure payments2019-10-012020-09-301,782USD2022-01-05
Revenue2019-10-012020-09-3077USD2022-01-05
Financing cash flow2022-10-012023-09-30199,395USD2024-01-19
Investing cash flow2019-10-012020-09-30-1,782USD2022-01-05
Retained earnings or deficitAt date2023-09-30-20,454,025USD2024-01-19
Net property, plant and equipmentAt date2020-09-301,275USD2022-01-05
Share-based compensation expense2022-10-012023-09-30464,878USD2024-01-19
Operating income or loss2022-10-012023-09-30-1,864,370USD2024-01-19
Current assetsAt date2022-09-309,915USD2024-01-19
Interest expense2022-10-012023-09-3091,603USD2024-01-19
Current liabilitiesAt date2023-09-301,433,861USD2024-01-19
Current accounts payableAt date2023-09-30328,178USD2024-01-19
Net current accounts receivableAt date2015-09-304,794USD2016-01-22
Operating expenses2016-10-012017-09-30460,909USD2018-01-16
Net inventoryAt date2020-09-302,412USD2022-01-05
Gross profit2020-10-012021-09-30-2,412USD2023-01-09
Common shares outstandingAt date2023-09-30996,119,530shares2024-01-19
Additional paid-in capitalAt date2023-09-3018,022,916USD2024-01-19
Accumulated other comprehensive income or lossAt date2018-09-30971USD2019-12-31
Accumulated depreciation on property, plant and equipmentAt date2021-09-303,194USD2022-01-05
Comprehensive income or loss2019-10-012020-09-30-541,731USD2020-12-03
Net income available to common stockholders2019-10-012020-09-30-541,731USD2020-12-03
General and administrative expense2022-10-012023-09-301,864,370USD2024-01-19
Depreciation expense2020-10-012021-09-301,275USD2023-01-09
Depreciation, depletion and amortization2014-10-012015-09-3020,574USD2016-01-22
Nonoperating income or expense2022-10-012023-09-30-84,879USD2024-01-19
Proceeds from issuing common stock2022-10-012023-09-3072,500USD2024-01-19
Change in accounts receivable2014-10-012015-09-30-11,097USD2016-01-22
Change in inventories2019-10-012020-09-30-36USD2022-01-05

Filings

53 GlobeStar Therapeutics filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
GlobeStar Therapeutics Corp / CIK 0001502152
Captured
2026-09-21T17:19:31.788Z
SEC response SHA-256
6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))